Active treatment with regimens including belantamab mafodotin or anti-CD38 monoclonal antibodies that deplete B-cells, as well as lymphopenia, were negative prognostic factors at the multivariate analysis, as they were correlated with lower antibody response rates. The gene discussed is CD38; the disease is lymphopenia.